139 related articles for article (PubMed ID: 9202333)
1. Aggregation state-dependent activation of the classical complement pathway by the amyloid beta peptide.
Webster S; Bradt B; Rogers J; Cooper N
J Neurochem; 1997 Jul; 69(1):388-98. PubMed ID: 9202333
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting the formation of classical C3-convertase on the Alzheimer's beta-amyloid peptide.
Emmerling MR; Spiegel K; Watson MD
Immunopharmacology; 1997 Dec; 38(1-2):101-9. PubMed ID: 9476121
[TBL] [Abstract][Full Text] [Related]
3. Amyloid fibril formation by a synthetic peptide from a region of human acetylcholinesterase that is homologous to the Alzheimer's amyloid-beta peptide.
Cottingham MG; Hollinshead MS; Vaux DJ
Biochemistry; 2002 Nov; 41(46):13539-47. PubMed ID: 12427014
[TBL] [Abstract][Full Text] [Related]
4. Complement activation by the amyloid proteins A beta peptide and beta 2-microglobulin.
Nybo M; Nielsen EH; Svehag SE
Amyloid; 1999 Dec; 6(4):265-72. PubMed ID: 10611947
[TBL] [Abstract][Full Text] [Related]
5. Alzheimer's beta-amyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner.
Bergamaschini L; Canziani S; Bottasso B; Cugno M; Braidotti P; Agostoni A
Clin Exp Immunol; 1999 Mar; 115(3):526-33. PubMed ID: 10193429
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of toxicity in the beta-amyloid peptide fragment beta -(25-35) using N-methylated derivatives: a general strategy to prevent amyloid formation.
Hughes E; Burke RM; Doig AJ
J Biol Chem; 2000 Aug; 275(33):25109-15. PubMed ID: 10825171
[TBL] [Abstract][Full Text] [Related]
7. Activation of complement and contact system in Alzheimer's disease.
Bergamaschini L; Donarini C; Gobbo G; Parnetti L; Gallai V
Mech Ageing Dev; 2001 Nov; 122(16):1971-83. PubMed ID: 11589915
[TBL] [Abstract][Full Text] [Related]
8. Complement activation by cross-linked truncated and chimeric full-length beta-amyloid.
Cribbs DH; Velazquez P; Soreghan B; Glabe CG; Tenner AJ
Neuroreport; 1997 Nov; 8(16):3457-62. PubMed ID: 9427307
[TBL] [Abstract][Full Text] [Related]
9. Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis.
Velazquez P; Cribbs DH; Poulos TL; Tenner AJ
Nat Med; 1997 Jan; 3(1):77-9. PubMed ID: 8986745
[TBL] [Abstract][Full Text] [Related]
10. Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide.
Bradt BM; Kolb WP; Cooper NR
J Exp Med; 1998 Aug; 188(3):431-8. PubMed ID: 9687521
[TBL] [Abstract][Full Text] [Related]
11. Induced expression of neuronal membrane attack complex and cell death by Alzheimer's beta-amyloid peptide.
Shen Y; Sullivan T; Lee CM; Meri S; Shiosaki K; Lin CW
Brain Res; 1998 Jun; 796(1-2):187-97. PubMed ID: 9689469
[TBL] [Abstract][Full Text] [Related]
12. The mouse C1q A-chain sequence alters beta-amyloid-induced complement activation.
Webster SD; Tenner AJ; Poulos TL; Cribbs DH
Neurobiol Aging; 1999; 20(3):297-304. PubMed ID: 10588577
[TBL] [Abstract][Full Text] [Related]
13. Common benzothiazole and benzoxazole fluorescent DNA intercalators for studying Alzheimer Aβ1-42 and prion amyloid peptides.
Stefansson S; Adams DL; Tang CM
Biotechniques; 2012 May; 52(5):. PubMed ID: 26307253
[TBL] [Abstract][Full Text] [Related]
14. [Physico-chemical methods for studing β-amyloid aggregation].
Radko SP; Khmeleva SA; Suprun EV; Kozin SA; Bodoev NV; Makarov AA; Archakov AI; Shumyantseva VV
Biomed Khim; 2015; 61(2):203-18. PubMed ID: 25978387
[TBL] [Abstract][Full Text] [Related]
15. Neuroglial-mediated immunoinflammatory responses in Alzheimer's disease: complement activation and therapeutic approaches.
Chen S; Frederickson RC; Brunden KR
Neurobiol Aging; 1996; 17(5):781-7. PubMed ID: 8892352
[TBL] [Abstract][Full Text] [Related]
16. Peripheral complement interactions with amyloid β peptide: Erythrocyte clearance mechanisms.
Brubaker WD; Crane A; Johansson JU; Yen K; Garfinkel K; Mastroeni D; Asok P; Bradt B; Sabbagh M; Wallace TL; Glavis-Bloom C; Tenner AJ; Rogers J
Alzheimers Dement; 2017 Dec; 13(12):1397-1409. PubMed ID: 28475854
[TBL] [Abstract][Full Text] [Related]
17. X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer's disease pathology.
Styren SD; Hamilton RL; Styren GC; Klunk WE
J Histochem Cytochem; 2000 Sep; 48(9):1223-32. PubMed ID: 10950879
[TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein E4 (ApoE4) but not ApoE3 or ApoE2 potentiates beta-amyloid protein activation of complement in vitro.
McGeer PL; Walker DG; Pitas RE; Mahley RW; McGeer EG
Brain Res; 1997 Feb; 749(1):135-8. PubMed ID: 9070638
[TBL] [Abstract][Full Text] [Related]
19. Beta-amyloid peptide in regulated secretory vesicles of chromaffin cells: evidence for multiple cysteine proteolytic activities in distinct pathways for beta-secretase activity in chromaffin vesicles.
Hook VY; Toneff T; Aaron W; Yasothornsrikul S; Bundey R; Reisine T
J Neurochem; 2002 Apr; 81(2):237-56. PubMed ID: 12064471
[TBL] [Abstract][Full Text] [Related]
20. Charged surfactants induce a non-fibrillar aggregation pathway of amyloid-beta peptide.
Loureiro JA; Rocha S; Pereira Mdo C
J Pept Sci; 2013 Sep; 19(9):581-7. PubMed ID: 23922329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
